VIDEO DESCRIPTION:

Play, download and edit the free video 21008_15AnnualMS_Live_vF.mp4.

Live Webinar - Tuesday, July 27th – 7:00 pm – 8:30 pm ET

ACTIVITY OVERVIEW
Although there is no medication that can fully prevent or reverse the neurologic deterioration associated with multiple sclerosis (MS), the use of disease-modifying therapy (DMT) is widely recommended to favorably impact prognosis and reduce disability. The number of DMTs now approved by the US Food and Drug Administration has grown substantially, resulting in more options for patients, but also increasing the complexity of starting, stopping, and switching treatments for healthcare providers (HCPs), who must consider the different modes of administration (injectable, oral, or intravenous), pharmacologic profiles, and benefit-risk profiles, in the context of individual- and disease-specific factors. Thus, although it is encouraging to have many options that have been shown to reduce the frequency and severity of relapses, to limit the development of new lesion activity, and to delay the progression of disability, many clinicians struggle to find the time and skills needed to appraise the large body of available safety and efficacy data for these DMTs and to translate that information into optimal treatment choices for their patients. Furthermore, suboptimal management of the whole patient (ie, focusing on the symptoms or relapses while ignoring other impacts and burdens on the patient), and the lack of shared decision-making may result in the selection of a treatment approach that is out of sync with an individual’s values, preferences, and therapy goals.

Management of MS as a chronic, multifaceted disease requires multidisciplinary care from a collaborative team of specialty and primary care HCPs. This opportunity seeks to facilitate this team-based care by providing education in a format that addresses both the unique and common educational needs of specialty and primary care HCPs, provides a forum in which to share the latest evidence-based information, and explores best practices for MS care in a primary care setting, specialty setting, and collaborative setting.

TARGET AUDIENCE
This activity is intended for Primary care clinicians (physicians, NPs, PAs), nurses, neurology clinicians (physicians, NPs, PAs), advanced practice nurses and other healthcare providers who may participate in the assessment and care of individuals with MS.

LEARNING OBJECTIVES
Upon completion of this activity, the learner should be able to:
• Facilitate strategies that support the early recognition and treatment of multiple sclerosis
• Assess clinical trial and real-world efficacy and safety data for DMTs recently approved for relapsing and progressive forms of MS 
• Propose effective shared decision making and collaborative care strategies to optimize MS management plans 

FACULTY
Scott Newsome, DO, MSCS, FAAN, FANA (Chairperson)
Associate Professor of Neurology
Director, Neurosciences Consultation and Infusion Center at Green Spring Station
Director, Stiff Person Syndrome Center
Co-Director, Multiple Sclerosis Experimental Therapeutics Program
Co-Director, Johns Hopkins Neuroimmunology Clinical Fellowship Program
Member, Miller-Coulson Academy of Clinical Excellence
Johns Hopkins Hospital
Division of Neuroimmunology and Neuroinfectious Diseases
Baltimore, Maryland

Lisa Fox, PA
Department Associate Director
Neurology Outpatient Infusion Center
Johns Hopkins Medical Center
Baltimore, Maryland

Jiwon Oh, MD, PhD, FRCPC
Staff Neurologist
Medical Director, of the Barl Multiple Sclerosis Program
St. Michael’s Hospital
University of Toronto
Toronto, Canada

COMMERCIAL SUPPORT
This activity is supported by an educational grant from Biogen and Bristol-Myers Squibb.

Download, play and edit free videos and free audios from 21008_15AnnualMS_Live_vF.mp4 using RedcoolMedia.net web apps